EyeGate Pharmaceuticals Reports Second Quarter 2016 Financial Results and Provides Business Update
10 août 2016 16h50 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 10, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a clinical-stage specialty pharmaceutical company that focuses on...
EyeGate Announces Positive Top-line Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Post-Operative Inflammation and Pain in Cataract Surgery Patients
01 août 2016 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., Aug. 01, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Announces Completion of $3.77 Million Registered Direct Offering
30 juin 2016 13h00 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., June 30, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Announces $3.77 Million Registered Direct Offering
27 juin 2016 08h00 HE
|
Eyegate Pharmaceuticals, Inc.
WALTHAM, Mass., June 27, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Announces Encouraging Interim Data from Phase 1b/2a Clinical Trial of EGP-437 for Treatment of Ocular Inflammation and Pain Post Cataract Surgery
01 juin 2016 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., June 01, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Pharma Announces At The Market Issuance Program
24 mai 2016 18h00 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., May 24, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (the “Company”) announced today that it has entered into an At The Market Issuance ("ATM") Sales...
Eyegate Pharmaceuticals Reports First Quarter 2016 Financial Results and Provides Business Update
13 mai 2016 17h25 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., May 13, 2016 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Pharma Appoints Dr. Brenda K. Mann as Vice President, Research and Development
06 mai 2016 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., May 06, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Pharma Appoints Ryan R. Brenneman as Chief Financial Officer
27 avr. 2016 16h05 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., April 27, 2016 (GLOBE NEWSWIRE) -- EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...
EyeGate Pharma to Present Four Posters at ARVO 2016 Annual Meeting Supporting Development of CMHA-S
26 avr. 2016 08h30 HE
|
EyeGate Pharmaceuticals, Inc.
WALTHAM, Mass., April 26, 2016 (GLOBE NEWSWIRE) -- Eyegate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and...